Dostarlizumab.pptx
- 2. Introduction
• USFDA approved (11Aug2021)
• TSR-042, JEMPERLI
• IgG 4k isotype
• Endometrial cancer
• Block PD-1
• Route of administration – intravenous
• Dmmr- deficient mismatch repair genetic abnormalities that disrupts
DNA repair